At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 33 enrolled
Drug / intervention
Raltegravir and truvada +1 moredrug
Likely dose
Raltegravir and truvada 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study--randomized, Prospective, Single Site Trial Evaluating Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients
The University of Texas Health Science Center, Houston·interventional·Posted Sep 30, 2008·Updated Jan 5, 2015
In Brief
A Phase 4 clinical trial evaluating Raltegravir and truvada and Atazanavir, Norvir and Truvada for HIV Infections. Completed, enrolled 33 participants across 1 site.
Detailed Summary
This is a pilot that will evaluate two regimens for treating HIV infected patients that haven't been on treatment before. HIV/AIDS patients may have an increased risk of myocardial infarction and antiretroviral therapy used may contribute to this. We will evaluate virological, immunological and cardiovascular effects of two HIV treatment regimens.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2008
Enrollment StartJan 2009
Primary CompletionDec 2012
Study CompletionJan 2013
TodayJul 2026
First PostedSep 30, 2008
Enrollment StartJan 1, 2009
Primary CompletionDec 1, 2012
Study CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 17.8 years ago
Interventions
Raltegravir and truvadadrug
Raltegravir 400 mg po bid, truvada 1 tab q daily
Atazanavir, Norvir and Truvadadrug
Atazanavir 300 mg po q daily, Norvir 100 mg po q daily and Truvada 1 tablet po q daily